Benchmark maintains Speculative Buy rating on Milestone Scientific stock

Investing.com - Benchmark maintained its Speculative Buy rating and $1.25 price target on Milestone Scientific (NYSE:MLSS) stock, citing progress in the Medicare market segment for its CompuFlo System. This target represents significant upside potential, with analysts’ targets ranging from $1.25 to $2.00.

The medical device company ended the second quarter with $1.3 million in cash and maintains a healthy current ratio of 2.03. With a market capitalization of $46.35 million and impressive gross margins of 72.8%, Milestone Scientific has secured coverage from three of the twelve Medicare Administrative Contractors for its pain management system.

Benchmark noted the "attractive value proposition" of Milestone’s technology for pain management providers, which could drive growth in the Medicare market segment that represents approximately 3.6 million procedures annually.

The research firm stated that Milestone plans to leverage relationships from its new management team to increase penetration in existing markets.

Benchmark’s $1.25 price target is based on 5 times its 2030 revenue estimate of $26 million, discounted to the end of 2025 at 8.3%, which the firm identified as Milestone Scientific’s weighted average cost of capital.

In other recent news, Milestone Scientific reported its financial results for the second quarter of 2025, showing a slight miss in earnings and a revenue shortfall compared to forecasts. The company’s earnings per share (EPS) registered a loss of $0.02, which was below the anticipated loss of $0.01. Revenue for the quarter reached $2.3 million, falling short of the expected $2.6 million. Despite these figures, the company’s stock experienced notable premarket activity. These developments are part of the latest updates surrounding Milestone Scientific.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.